Add Yahoo as a preferred source to see more of our stories on Google. We often hear a lot of talk relating to our hormones, but according to Dr. Juliana M. Kling, M.D., M.P.H., a Women’s Health ...

Considering the fact that every woman on earth who lives long enough goes through menopause, it’s astounding that the subject is still so hush-hush. Fortunately, medical researchers are devoting more ...

Neurokinin is crucial in the pathophysiology of vasomotor symptoms linked to menopause, offering a target for novel treatments. Fezolinetant, a nonhormonal agent, antagonizes neurokinin-3 receptors to ...

According to the North American Menopause Society, hormone therapy remains the most effective treatment for menopause-related VMS. 9 However, many women have refused hormone therapy, especially since ...

The genetic causes of very early menopause will have to be reconsidered after researchers found that nearly all women who carried variations thought to cause the condition in fact had their menopause ...

Midlife migraine is a strong indicator of a more difficult menopause transition, with women who have a recent history of migraine being more likely to experience vasomotor symptoms (VMS). Severe VMS ...

While no one understands the exact mechanism behind VMS, their trigger is mostly due to the decline of estrogen at the time of menopause, explains Lisa Brent, ND, founder and medical director of Be ...

Natural menopause is due to the age-related decline in ovarian follicles and the accompanying changes in hormones. Early menopause can be caused by surgery, cancer treatments, and other medical ...

GoodRx reports that certain antidepressants can reduce menopause symptoms, especially hot flashes, with Brisdelle being the ...

BERLIN--(BUSINESS WIRE)--Bayer today announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the U.S. Food and Drug Administration (FDA) for the ...

Late-breaking data from pivotal Phase III studies OASIS 1 and 2 to be presented at 2024 ACOG Annual Meeting: Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a ...